Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Oct 1, 2020 • 8:24 AM EDT
Ligand Completes Acquisition of Pfenex Inc.
Sep 30, 2020 • 8:00 AM EDT
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
Sep 23, 2020 • 8:00 AM EDT
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Sep 14, 2020 • 1:00pm EDT
See all events
Aug 3, 2020 • 5:30pm PDT
Jun 10, 2020 • 8:30am PDT